Piccart MJ - Search Results

1

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group. Di Leo A, et al. Among authors: piccart mj. Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12. Lancet Oncol. 2011. PMID: 21917518 Free article.

2

Adjuvant systemic therapy for breast cancer.

Piccart MJ, Biganzoli L, Roy JA. Piccart MJ, et al. Curr Opin Oncol. 1996 Nov;8(6):478-84. doi: 10.1097/00001622-199611000-00006. Curr Opin Oncol. 1996. PMID: 8971467 Review.

3

Future perspectives of docetaxel (Taxotere) in front-line therapy.

Piccart MJ, Di Leo A. Piccart MJ, et al. Semin Oncol. 1997 Aug;24(4 Suppl 10):S10-27-S10-33. Semin Oncol. 1997. PMID: 9275004 Review.

4

Breast cancer therapies in development. A review of their pharmacology and clinical potential.

de Valeriola D, Awada A, Roy JA, Di Leo A, Biganzoli L, Piccart M. de Valeriola D, et al. Drugs. 1997 Sep;54(3):385-413. doi: 10.2165/00003495-199754030-00003. Drugs. 1997. PMID: 9279502 Review.

5

Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer.

Di Leo A, Piccart MJ. Di Leo A, et al. Among authors: piccart mj. Semin Oncol. 1999 Jun;26(3 Suppl 8):27-32. Semin Oncol. 1999. PMID: 10403471 Review.

6

A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer.

Di Leo A, Crown J, Nogaret JM, Duffy K, Bartholomeus S, Dolci S, Rowan S, O'Higgins N, Paesmans M, Larsimont D, Riva A, Piccart MJ. Di Leo A, et al. Among authors: piccart mj. Ann Oncol. 2000 Feb;11(2):169-75. doi: 10.1023/a:1008345432342. Ann Oncol. 2000. PMID: 10761751 Free article. Clinical Trial.

7

The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?

Piccart MJ, Biganzoli L, Di Leo A. Piccart MJ, et al. Eur J Cancer. 2000 Apr;36 Suppl 1:S4-10. doi: 10.1016/s0959-8049(99)00256-7. Eur J Cancer. 2000. PMID: 10785603 Review.

8

Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases.

Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di Leo A, Nogaret JM, Hertens D, Verhest A, Larsimont D. Gancberg D, et al. Am J Clin Pathol. 2000 May;113(5):675-82. doi: 10.1309/0F58-0GRX-FK4R-A6VA. Am J Clin Pathol. 2000. PMID: 10800400

9

HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?

Piccart MJ, Di Leo A, Hamilton A. Piccart MJ, et al. Eur J Cancer. 2000 Sep;36(14):1755-61. doi: 10.1016/s0959-8049(00)00162-3. Eur J Cancer. 2000. PMID: 10974622 Review.

10

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.

Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J. Tanner M, et al. Among authors: piccart mj. Am J Pathol. 2000 Nov;157(5):1467-72. doi: 10.1016/S0002-9440(10)64785-2. Am J Pathol. 2000. PMID: 11073807 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

605 results

Search Page

Filters